DERM
NASDAQJourney Medical Corporation
Journey Medical Corporation (DERM) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for DERM, including 2 earnings updates and 2 SEC filings. The most recent was published Nov 12, 2026.
DERM rankings
Financial highlights
Full financials- Revenue, TTM
- $68.18M
- Revenue growth
- +20.9%
- Net income, TTM
- -$6.10M
- Net margin
- -9.0%
- Cash
- $25.64M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks22+300%
2026-05-172026-11-08
Mix790d
- Other2(29%)
- Earnings2(29%)
- SEC Filings2(29%)
- Leadership1(14%)
Activity · 52 weeks4224 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Journey Medical Corporation10-Q - Journey Medical Corp (0001867066) (Filer)
- SECJourney Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsTotal revenues were $19.0 million for the third quarter of 2026 Emrosi® revenues of $9.0 million increased 84% compared to the third quarter of 2025 Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2026. "We continued to make progress during the thi
- PRJourney Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2026 financial results after the U.S. financial markets close on Thursday, November 12, 2026. Journey Medical management will conduct a conference call and audio webcast on Thursday, November 12, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties w
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Journey Medical CorporationSCHEDULE 13G/A - Journey Medical Corp (0001867066) (Subject)
- PRJourney Medical Corporation to Participate in September 2026 Investor ConferencesSCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences. Details of the events are as follows: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) ConferenceDate: Thursday, September 10, 2026Location: New York CityFormat: 1x1 Meetings H.C. Wainwrigh
- PRLongeveron Appoints Nirav Jhaveri as Chief Financial OfficerMr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer ("CFO"), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped into the role following the retirement of the
- SECSEC Form 10-Q filed by Journey Medical Corporation10-Q - Journey Medical Corp (0001867066) (Filer)
- SECJourney Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsTotal revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi® revenues were $8.1 million for the second quarter of 2026 Strong revenue growth and disciplined cost management continue drive to profitability Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial result
- PRJourney Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, August 12, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties wi
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Journey Medical CorporationSCHEDULE 13G/A - Journey Medical Corp (0001867066) (Subject)
- INSIDERDirector Toledano Miranda Jayne was granted 50,000 shares, increasing direct ownership by 42% to 168,618 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- INSIDERDirector Smith Justin Adam was granted 50,000 shares, increasing direct ownership by 28% to 231,618 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- INSIDERDirector Herskowitz Neil was granted 50,000 shares, increasing direct ownership by 42% to 168,618 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- INSIDERDirector Toledano Miranda Jayne was granted 10,000 shares, increasing direct ownership by 9% to 118,618 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- INSIDERDirector Smith Justin Adam was granted 10,000 shares, increasing direct ownership by 6% to 181,618 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- INSIDERDirector Herskowitz Neil was granted 10,000 shares, increasing direct ownership by 9% to 118,618 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- INSIDERDirector Pearce Michael Cooper was granted 10,000 shares, increasing direct ownership by 17% to 67,173 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- INSIDERDirector Rosenwald Lindsay A Md was granted 10,000 shares, increasing direct ownership by 5% to 221,146 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- SECJourney Medical Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare ConferenceSCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET. To register for the conference, visit the A.G.P. Registration Link. About Journey Medical Corpora
- SECSEC Form 10-Q filed by Journey Medical Corporation10-Q - Journey Medical Corp (0001867066) (Filer)
- SECJourney Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsTotal revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corp
DERM FAQ
11 questionsWhat does Journey Medical Corporation do?
Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm...What is the latest news on DERM?
In the last 30 days Quantisnow tracked 4 wire items for DERM: 2 earnings updates and 2 SEC filings. The most recent was published on November 12, 2026.What is DERM revenue?
Journey Medical Corporation (DERM) reported $68.18M of revenue for the twelve months ended Jun 30, 2026. That is up 20.9% from the year before. Revenue for fiscal 2025 was $61.86M.Is DERM profitable?
No. Journey Medical Corporation reported a net loss of $6.10M for the twelve months ended Jun 30, 2026.How much cash and debt does DERM have?
Journey Medical Corporation reported $25.64M in cash and cash equivalents and $25.47M of debt on its most recent balance sheet in SEC filings.Where does DERM stock trade?
Journey Medical Corporation (DERM) is listed on NASDAQ.What sector and industry is DERM in?
Journey Medical Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Journey Medical Corporation go public?
Journey Medical Corporation (DERM) completed its IPO in 2021.What are analysts saying about DERM?
Journey Medical Corporation has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $13.00 price target on 2025-08-25. Recent price targets range from $9.00 to $15.00.What companies are similar to DERM?
Notable peers in the same industry include VRCA (Verrica Pharmaceuticals Inc.), OGN (Organon & Co.), SLGL (Sol-Gel Technologies Ltd.). Compare DERM side-by-side with any of them on Quantisnow.How can I track DERM on Quantisnow?
Quantisnow aggregates Journey Medical Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DERM to receive live email and push alerts on every new disclosure.